Deciphering the Mechanisms of Therapeutic Protein Production

摘要

Preduction of therapeutic recombinant proteins from mammalian systems is one of the fastest growing segments of the pharmaceutical market(2).Several analyses indicate that demand will eventually outpace production of these proteins.This imminent shortage has served to emphasize the need to improve on the yield that can be obtained from the systems currently in place.The majority of these proteins are produced in Chinese Hamster Ovary(CHO)cells,while the remainder are produced in a variety of other cell types including mouse myelomas NSO and SP2/0,baby hamster kidney(BHK)and a variety of others.CHO cells were first cultured in the late 1950's after their isolation from a Chinese hamster(Cricetulus griseus)ovary epithelial tumor(2).Produced in CHO,tPA was the first of these recombinant proteins to receive approval for therapeutic use in 1986(3).Many changes to the process have occurred since that time,including changes to the cells,the growth medium and the reactor conditions to improve from that first venture.